Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8754663 | 0.80 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL5093242 | 0.80 | CYP1A2 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL1115865 | 0.80 | CYP1A2 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL5510083 | 0.80 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL8754671 | 0.80 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL456812 | 0.80 | CYP1A2 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL6535913 | 0.80 | CYSLTR1 (0.46) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL6525088 | 0.79 | CYSLTR1 (0.52) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL27924057 | 0.77 | CYP1A2 (0.44) | CYSLTR1CYSLTR2PDE10ACYP1A2GPBAR1 | |
| SCHEMBL28009473 | 0.77 | LMNA (0.54) | CYSLTR1CYSLTR2CYP1A2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209530-A1 | POWDER ORAL SUSPENSION FORMULATIONS OF ANTIBACTERIAL AGENTS | TETARD, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20170224664-A1 | POWDER ORAL SUSPENSION FORMULATIONS OF ANTIBACTERIAL AGENTS | CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT | 2017-08-10 | — | — | US | disclosed |
| EP-3185864-A1 | POWDER ORAL SUSPENSION FORMULATIONS OF ANTIBACTERIAL AGENTS | Cempra Pharmaceuticals, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016022658-A1 | POWDER ORAL SUSPENSION FORMULATIONS OF ANTIBACTERIAL AGENTS | CEMPRA PHARMACEUTICALS, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209530-A1 | POWDER ORAL SUSPENSION FORMULATIONS OF ANTIBACTERIAL AGENTS | RPN2, MRPL21, SBDS | CYSLTR1 4155/4885CYSLTR2 4368/4885PDE10A 2542/4885 |
| US-20170224664-A1 | POWDER ORAL SUSPENSION FORMULATIONS OF ANTIBACTERIAL AGENTS | RPN2, MRPL21, SBDS | CYSLTR1 4155/4885CYSLTR2 4368/4885PDE10A 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.